Trade Mark Journal No.2026/011 13 March 2026
UK00004345395 25 February 2026 (5,40,42)
CALLIO THERAPEUTICS
International priority date claimed: 26 August 2025
(United States of America)
(99357977)
- Class 5
- Pharmaceutical and biological preparations for treating cancer; Pharmaceuticals and biological preparations for prophylactic, diagnostic, and therapeutic use in treating, preventing, and managing cancer; Therapeutic agents for medical use, namely, proteins and derivatives, antibody-drug conjugates, immunostimulatory antibody-drug conjugates, antibodies with multiple drug or cytokine conjugates, multispecific antibodies, and engineered antibodies for treating cancer; Pharmaceutical and biological preparations for the prevention, diagnosis and treatment of cancer for clinical, medicinal, therapeutic and diagnostic purposes; Pharmaceutical and biological preparations for use in oncology for treating cancer.
- Class 40
- Custom manufacturing of pharmaceuticals and therapeutic agents for medical use.
- Class 42
- Research and development in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory antibody-drug conjugates, antibodies with multiple drug or cytokine conjugates, multispecific antibodies, and engineered antibodies, oncology; Providing medical scientific research information in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory anti-drug conjugates, antibodies with multiple drug or cytokine conjugates, multispecific antibodies, and engineered antibodies, oncology, and immunology; Drug discovery, custom design, and development services featuring therapeutic agents for the treatment and prevention of diseases; Scientific investigations for medical purposes; Scientific research in the nature of conducting clinical trials for others.
Callio Operating Co, Inc.
Representative: Mewburn Ellis LLP